Influence of Simvastatin on Pharmacokinetics/Pharmacodynamics of Aspirin after Oral Co-administration in Healthy Volunteers

건강한 자원자에서 아스피린과 심바스타틴 병용투여 시, 심바스타틴이 아스피린의 약동학/약력학적 특성에 미치는 영향

  • Gu, Nam-Yi (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Kim, Bo-Hyung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Chung, Yong-Ju (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Lim, Kyoung-Soo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Seo, Hyo-Bum (Clinical Research Coordinating Center, Catholic Medical Center) ;
  • Yim, Dong-Seok (Department of Pharmacology, College of Medicine, the Catholic University of Korea) ;
  • Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital) ;
  • Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine andhospital)
  • 구남이 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김보형 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 정용주 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 임경수 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 서효범 (가톨릭중앙의료원 임상연구지원센터) ;
  • 임동석 (가톨릭대학교 의과대학 약리학교실 및 서울성모병원 임상약리학과) ;
  • 신상구 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 유경상 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과)
  • Received : 2011.11.07
  • Accepted : 2011.12.09
  • Published : 2011.12.30

Abstract

Background: Both aspirin and simvastatin are prescribed as treatments or prevention of cardiovascular diseases. The aim of this study was to investigate the influence of simvastatin on pharmacokinetics and pharmacodynamics of aspirin after oral co-administration in healthy subjects. Methods: Subjects were orally administered aspirin 100 mg for 7 days followed by co-administration of aspirin 100 mg and simvastatin 40 mg for 7 days once daily. A series of blood samples were collected before and till 24hours after drug administration on Day 1 (single-dose of aspirin), Day 7 (multiple-dose of aspirin) and Day 14 (multiple-dose of aspirin and simvastatin). The effects of simvastatin on pharmacokinetics of acetylsalicylic acid and salicylic acid were assessed with the 90 % confidence intervals (CIs) of thegeometric mean ratios (GMRs) of Day 14 over Day 7 for maximum plasma concentration ($C_{max}$) and the area under the concentration-time curve ($AUC_{0-24}$). Pharmacodynamics was assessed with maximal changes of platelet aggregation from baseline. Results: Twenty-fourhealthy men aged 20 to 36 years were enrolled and 23 of them completed the study. GMRs (90 % CIs) of $C_{max}$ and $AUC_{0-24}$ for acetylsalicylic acid were 1.21 (1.04 - 1.42) and 1.28 (1.19 - 1.38), respectively. For salicylic acid, GMRs of $C_{max}$ and $AUC_{0-24}$ were 0.96 (0.91 - 1.00) and 1.00 (0.97 - 1.04), respectively. Maximal changes of platelet aggregation on Day 7 and Day 14 from baseline were not significantly different (p=0.41); $87.5{\pm}8.8$ % and $87.3{\pm}9.2$ %, respectively. Conclusion: Coadministration of simvastatin slightly increased the systemic exposure of acetylsalicylic acid with no changes of systemic exposure of salicylic acid or inhibition of platelet aggregation.

Keywords

Acknowledgement

Supported by : 보령제약(주)

References

  1. Buchanan, MR, Rischke, JA, hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res, 1982;25(5):363-373. https://doi.org/10.1016/0049-3848(82)90127-X
  2. Lemos SR, Carvalho SJ, Calisto CB, Nogueira JM, Ravara L. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations. Rev Port Cardiol, 2007;26(7-8):769-788.
  3. Sirtori CR. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res, 1990;22(5):555-563. https://doi.org/10.1016/S1043-6618(05)80047-7
  4. Hebert PR, gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA, 1997;278(4):313-321. https://doi.org/10.1001/jama.1997.03550040069040
  5. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther, 2008;6(1):95-107. https://doi.org/10.1586/14779072.6.1.95
  6. Nimpf J, Wurmh, KostnergM, Kenner T. Platelet activation in normo- and hyperlipoproteinemias. Basic Res Cardiol, 1986;81(5):437-453. https://doi.org/10.1007/BF01907750
  7. Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ, 2003;326(7380):82-83. https://doi.org/10.1136/bmj.326.7380.82
  8. Undas A, Siudak Z, Topor-Madry R, Lesniak M, Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation. Int J Cardiol, 2012;154(1):59-64. https://doi.org/10.1016/j.ijcard.2010.09.093
  9. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronaryheart disease events in men: a cost-utility analysis. Ann Intern Med, 2006;144(5):326-336. https://doi.org/10.7326/0003-4819-144-5-200603070-00007
  10. Kees F, Jehnich D, grobecker H. Simultaneous determination of acetylsalicylic acid and salicylic acid inhuman plasma byhigh-performance liquid chromatography. J Chromatogr B Biomed Appl, 1996;677(1):172-177. https://doi.org/10.1016/0378-4347(95)00464-5
  11. McMahon GP, Kelly MT. Determination of aspirin and salicylic acid inhuman plasma by column-switching liquid chromatography using on-line solid-phase extraction. Anal Chem, 1998;70(2):409-414. https://doi.org/10.1021/ac9707040
  12. Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD. Quantitation of simvastatin and its beta-hydroxy acid inhuman plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom, 2000;35(9):1133-1143. https://doi.org/10.1002/1096-9888(200009)35:9<1133::AID-JMS42>3.0.CO;2-X
  13. Yang AY, Sun L, Musson DG, Zhao JJ. Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid inhuman plasma. J Pharm Biomed Anal, 2005;38(3):521-527. https://doi.org/10.1016/j.jpba.2005.01.016
  14. Kim J, Ahn BJ, Chae HS, han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS. A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primaryhyperlipidaemia. Basic Clin Pharmacol Toxicol, 2011;109(3):156-163. https://doi.org/10.1111/j.1742-7843.2011.00700.x
  15. Mardikarh, Deo D, Deshpande N, Mardikar M, Ghosh A, Munot K, Steinhubl S, Mukherjee D. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in ahigh risk population. J Assoc Physicians India, 2008;56:321-324.
  16. Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet, 1985;10(5):392-403. https://doi.org/10.2165/00003088-198510050-00002
  17. Yang F, Bian C, Zhu L, Zhaog,huang Z, Huang M. Effect ofhuman serum albumin on drug metabolism: structural evidence of esterase activity ofhuman serum albumin. J Struct Biol, 2007;157(2):348-355. https://doi.org/10.1016/j.jsb.2006.08.015
  18. Honma K, Nakamura M, Ishikawa Y. Acetylsalicylate-human serum albumin interaction as studied by NMR spectroscopy-antigenicity-producing mechanism of acetylsalicylic acid. Mol Immunol, 1991;28(1-2):107-113. https://doi.org/10.1016/0161-5890(91)90093-Y
  19. Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs onhuman carboxylesterase activities. Drug Metab Dispos, 2010;38(12):2173-2178. https://doi.org/10.1124/dmd.110.034454
  20. Jang SB, Lee YJ, Lim LA, Park KM, Kwon BJ, Woo JS, Kim YI, Park MS, Kim KH, Park K. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin inhealthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin Ther, 2010;32(1):206-216. https://doi.org/10.1016/j.clinthera.2010.01.026
  21. Roensch J, Crisby M, Nordberg A, Xiao Y, Zhang LJ ,guan ZZ. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int, 2007;50(6):800-806. https://doi.org/10.1016/j.neuint.2007.02.001
  22. Van Lith HA, MeijergW,haller M, Beynen AC. Serum pseudocholinesterase activity in rabbits fed simvastatin. Biochem Pharmacol, 1991;41(3):460-461. https://doi.org/10.1016/0006-2952(91)90546-H
  23. Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents onhuman cholinesterases. Clin Biochem, 2004;37(1):42-49. https://doi.org/10.1016/j.clinbiochem.2003.09.004
  24. Muacevic-Kataneca D, Bradamante V, Reinec Z, Sucic M, Poljicanin T, Busljeta I, Metelko Z. Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Arzneimittelforschung, 2005;55(5):271-275.
  25. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN. ACC/AHAguidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/Americanheart Association task force on practiceguidelines (committee on the management of patients with unstable angina). Circulation, 2000;102(10):1193-1209. https://doi.org/10.1161/01.CIR.102.10.1193
  26. Bertrand ME, Simoons ML, Fox KA, Wallentin LC,hamm CW, McFadden E, de Feyter PJ, Specchiag, Ruzyllo W. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J, 2000;21(17):1406-1432. https://doi.org/10.1053/euhj.2000.2301